(Total Views: 564)
Posted On: 04/02/2025 3:12:43 PM
Post# of 154743
We've claimed Oncology/solid tumors as focus.
100% ok with chasing a FDA salvage trial based on 36+. Data is so phenomenal, mono approval should not be a "100+" trial.
Especially if ( I expect ) 100% of our ladies survived not only past Trodelvy's p 21 months, but significantly past.
If say "$75m" gets us a FDA mono/salvage line mTNBC approval, that's an easy amount to raise in the cancer world. 1 approval & Dr 's prescribe LL for everything under the sun.
Media runs/advertising, sales teams & no need to liscence away value in other diseases. Pump out Mfgr'ing for delivery.
Non-toxic & unprecedented low overhead.
100% ok with chasing a FDA salvage trial based on 36+. Data is so phenomenal, mono approval should not be a "100+" trial.
Especially if ( I expect ) 100% of our ladies survived not only past Trodelvy's p 21 months, but significantly past.
If say "$75m" gets us a FDA mono/salvage line mTNBC approval, that's an easy amount to raise in the cancer world. 1 approval & Dr 's prescribe LL for everything under the sun.
Media runs/advertising, sales teams & no need to liscence away value in other diseases. Pump out Mfgr'ing for delivery.
Non-toxic & unprecedented low overhead.
(9)
(0)
